Severe sepsis results in a sustained deleterious immune dysregulation. Indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism, plays a pivotal role in immune tolerance and is induced during various inflammatory conditions.
Background. Severe sepsis results in a sustained deleterious immune dysregulation. Indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism, plays a pivotal role in immune tolerance and is induced during various inflammatory conditions.
Methods. Plasma samples obtained from patients with septic shock ( ), severe sepsis ( ), or sepsis n p 38 n p 35 ( ) and from healthy donors ( ) were analyzed for IDO activity by high-performance liquid chron p 10 n p 26 matography. Lymphocyte, monocyte, and regulatory T cell counts as well as monocytic human leukocyte antigen DR (HLA-DR) expression were quantified by flow cytometry. Peripheral blood mononuclear cells and purified CD14 + and CD14 Ϫ fractions were assayed in vitro for spontaneous and inducible IDO expression and activity. Results. IDO activity gradually increased according to sepsis severity, and septic patients who died had higher IDO activity on admission than did survivors ( ). Monocytes were a major source of active IDO in normal P p .013 peripheral blood. The percentage and absolute number of circulating CD14 + cells were increased in septic patients, and their monocytes remained fully able to produce functional IDO after NF-kB-independent interferon g stimulation but not through NF-kB-dependent Toll-like receptor engagement.
Conclusions. IDO activity is increased during severe sepsis and septic shock and is associated with mortality. IDO production could be used to better characterize monocyte reprogramming in sepsis.
Septic shock, the systemic host response that occurs during severe infection, remains the leading cause of mortality in intensive care units (ICUs). Owing to recent advances in antibiotic and supportive therapies, most patients survive the initial intense proinflammatory response. However, they rapidly display clinical features consistent with an immunosuppressive state, including a loss of delayed-type hypersensitivity, an in-ability to eradicate infection, and a predisposition to nosocomial infections [1] [2] [3] . This sustained immune dysregulation is characterized by a reprogramming of leukocytes rather than by hyporeactivity. The main mechanisms demonstrated so far are (1) lymphopenia, associated with extensive apoptosis of T, B, and dendritic cells [1, 4] ; (2) an increase in the proportion of circulating regulatory T cells (Treg) that exhibit an enhanced suppressive activity [5, 6] ; and (3) marked alterations of monocyte phenotype and function exemplified by a reduced expression of HLA-DR [7, 8] , granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, CX3CR1 fractalkine receptor, and CD14, a loss of antigen-presenting capacity, and a defective production of inflammatory cytokines in response to in vitro challenge with bacterial compounds [9] [10] [11] [12] . Monocyte dysfunction has been linked to several factors, including increased levels of interleukin 10 (IL-10) and cortisol or the direct inhibitory effect of Treg, and seems to be partially restored by interferon g (IFN-g) or GM-CSF treatment [13] [14] [15] [16] [17] . Among these alterations, the down-modulation of HLA-DR expression on monocytes and the intensity of lymphocyte apoptosis are associated with outcome in patients with sepsis when they persist over time [4, 18, 19] . Indoleamine 2,3-dioxygenase (IDO) plays a pivotal role in immune tolerance [20] . IDO catalyzes the first and limiting step of tryptophan catabolism, resulting in suppression of T cell proliferation in vitro and in vivo. In addition, the tryptophan-depleting activity of IDO affects the growth of several pathogens, so that IDO activation could have beneficial, as well as detrimental, consequences on host defences against infections. IDO can be induced in various cell types during infection, especially in response to IFN-g signaling and/or bacterial components such as Toll-like receptor (TLR) ligands. Recently, IDO blockade was demonstrated to protect mice against lipopolysaccharide (LPS)-induced endotoxin shock, in association with a modulation of interleukin 12 (IL-12) and IL-10 production by dendritic cells [21] . In humans, IDO activation has been reported in human immunodeficiency virus (HIV)-infected patients [22] and after major trauma [23] . Studies on IDO expression in human myeloid dendritic cells obtained by in vitro differentiation of monocytes showed that bioactive enzyme is inconstantly induced by various combinations of IFN-g, cytotoxic T-lymphocyte antigen 4 (CTLA-4), CD40-Ligand, prostaglandin E2, and TLR ligands such as LPS, poly(I:C), or peptidoglycan [24] [25] [26] [27] . However, little is known about circulating monocytes and macrophages in human diseases. Our objectives were (1) to study IDO activity in plasma obtained from patients with sepsis, (2) to investigate the association between IDO and other immunosuppression markers, and (3) to explore in vitro the effect of TLR ligands on IDO activity.
METHODS
Patients and control participants. This study was performed in the infectious diseases department and ICU at Rennes University Hospital. A total of 83 consecutive adult septic patients, including 38 patients with septic shock, 35 patients with severe sepsis, and 10 patients with sepsis, were prospectively enrolled and compared with 26 healthy control participants. The study design was approved by the institutional review board. Pregnant women, patients who were younger than 18 years old, patients with malignancy, HIV-infected patients, and patients receiving immunosuppressive agents were excluded. Standard criteria were used for diagnosis of septic shock, severe sepsis, and sepsis [28] . The Simplified Acute Physiology Score (SAPS II) at admission in ICU, and the Logistic Organ Dysfunction (LOD) system at day 0 and day 7 were used to assess severity of sepsis [29, 30] . Blood samples treated with heparin were collected for all patients within 24 h following sepsis diagnosis (day 0). When possible, additional samples were obtained [6] [7] [8] . HLA-DR cell surface den-10% sity was expressed as the ratio of mean fluorescence intensity evaluated on CD14 + cells. To evaluate the mechanism of CpGdependent IDO activation, freshly isolated PBMCs were stimulated for 3 h by 100 mg/mL CpG-C (Invivogen), with Golgi Plug protein transport inhibitor (Becton Dickinson) added for the last 2-h incubation as described elsewhere [31] . The percentage of interferon a (IFN-a) and IFN-g producing cells were then analyzed on Lin Ϫ HLA-DR + CD123 + plasmacytoid dendritic cells (pDCs) using the Cytofix/Cytoperm kit, as well as Lin1-FITC, HLA-DR-PerCP, IFN-a-PE (Miltenyi Biotech), IFN-g-PE (Becton Dickinson), and CD123-APC monoclonal antibodies (Miltenyi Biotech).
Cell isolation and culture. PBMCs isolated from healthy donors and septic patients were stimulated with IFN-g and microbial-derived TLR ligands. For some experiments, CD14 + and CD14
Ϫ fractions were further selected by using the CD14 isolation kit (Miltenyi Biotec) with a cell purity 196%. Whole PBMCs, CD14 + , and CD14 Ϫ cells were cultured at 10 6 cells/mL in Roswell Park Memorial Institute, or RPMI, 1640 medium-10% fetal calf serum (Biowest)-penicillin/streptomycin supplemented with 20 ng/mL macrophage-colony stimulating factor (R&D Systems) and were stimulated either by 50 IU/mL IFNg (R&D Systems), 10 ng/mL LPS, 4 mg/mL CpG-C (Invivogen), or 50 mg/mL Poly(I:C) (Sigma). In some experiments, IFN type I activity was blocked by a combination of 5 mg/mL anti-IFNa/b R2 with 2000 IU/mL anti-IFN-a monoclonal antibodies (PBL), and NF-kB signaling was inhibited by 20 mmol/L wedelolactone (Calbiochem). IDO expression and activity assessment. Human mesenchymal stem cells (MSCs) were used as positive control of IFNg-dependent IDO-producing cells and were obtained and characterized as described elsewhere [32] . RNA was extracted using RNeasy kit (Qiagen) from purified monocytes and mesenchymal stem cells unstimulated or treated for 3 days with IFN-g. Complementary DNA was generated using Superscript reversetranscriptase (Invitrogen). For quantitative polymerase chain reaction, we used assay-on-demand primers and probes, Taqman Universal MasterMix, and ABI Prism 7000 apparatus from Applied Biosystems. ABL was used as an internal standard gene. For immunofluorescence analysis, mesenchymal stem cells and monocytes were cultured on glass coverslips and fixed in 4% paraformaldehyde. Cells were stained with polyclonal IDO Ab (Thermo Fisher Scientific), followed by Alexa 455-conjugated donkey anti-sheep secondary antibodies (Invitrogen) and analyzed by confocal microscopy (SP2, Leica). ImageJ software was used for image analysis. Finally, IDO activity was evaluated by measuring kynurenine and tryptophan levels in plasma samples and cell-culture supernatants with high-performance liquid chromatography, using 3-nitro-L-tyrosine as an internal standard [32] . IDO activity was maximal in culture after 3 days of IFN-g stimulation for both monocytes and PBMCs, so that all in vitro experiments were stopped at 72 h.
Statistical analysis. Quantitative variables were expressed as median and interquartile range (IQR). Differences observed between groups were first analyzed using the nonparametric Kruskall-Wallis test followed by the Mann-Whitney U test. Because of multiple comparisons, the a level was adjusted according to the Bonferroni correction. Differences observed between day 0 and day 7 were analyzed using the Wilcoxon matched-pairs signed-ranks test. Correlations between 2 continuous variables were investigated using the nonparametric Spearman rank correlation test. IDO activities in cell-culture supernatants were compared using the Mann-Whitney U test.
RESULTS

Enhanced IDO activity in sepsis is associated with severity.
The characteristics of septic patients and healthy donors are summarized in Table 1 , and sepsis etiology is detailed in Table  2 . On day 0, IDO activity was markedly increased in patients Tryptophan and kynurenine concentrations were measured by high-performance liquid chromatography in plasma samples collected from 26 healthy donors and from 83 septic patients at diagnosis (day 0), including 10 patients with sepsis (Se), 35 with severe sepsis (Sse), and 38 with septic shock (Ssh). On day 7, data are available for 49 of the 83 septic patients, including 6 with sepsis, 22 with severe sepsis, and 21 with septic shock. Horizontal lines from the bottom to the top represent the 10th, 25th, 50th (median), 75th, and 90th percentiles. Circles represent outlying values. Statistical analyses were used to compare each patient group vs control group (* ; ** ; *** ). (B ) IDO activity in surviving (S) vs nonsurviving P ! .05 P ! .01 P ! .001 (NS) septic patients. Patients were defined as survivors if they were alive at day 30 and as nonsurvivors if they died before day 30. Box plot distributions of the kynurenine/tryptophan ratio are for day 0 (66 survivors, 17 nonsurvivors) and at day 7 (42 survivors, 7 nonsurvivors). * ; ** ; P ! .05 P ! .01 *** ; ns, not significant. Figure 1A) . Notably, IDO activity gradually heightened with sepsis severity, from nonsevere sepsis to severe sepsis ( ), and from severe sepsis P ! .001 to septic shock ( ), compared with control participants, whereas it had P ! .001 returned to normal values at day 7 in patients with nonsevere sepsis ( Figure 1A) . IDO activity at day 0 was correlated with day 0 SAPS II score ( , ) and day 0 LOD score r p 0.424 P ! .001 ( ; ). IDO activity at day 7 was correlated with r p 0.479 P ! .001 day 7 LOD score ( ; ). IDO activity was still r p 0.629 P ! .001 higher for the 8 patients with severe sepsis or septic shock in whom samples were obtained at day 14 than in control participants (
). Increases in IDO activity resulted from P p .006 the combination of reduced tryptophan concentration and increased kynurenine level at each time point. Altogether, these data indicate a striking IDO-mediated tryptophan degradation in septic patients that is persistent and parallels sepsis severity.
Enhanced IDO activity in sepsis is associated with unfavorable outcome. Mortality, defined as death occurring within 30 days after sepsis diagnosis, was 20% in the overall septic population and reached 42% in the patient group with septic shock (Table 1) ) ( Figure 1B ). In addition, IDO activity, although not P p .005 fully reverted to its normal value, decreased between day 0 and day 7 in survivors (Ϫ46.5%; ), whereas it did not sig-P ! .001 nificantly change in nonsurvivors.
Enhanced IDO activity in sepsis is not correlated with lymphocyte or monocyte alterations. Because prolonged lymphopenia, increased percentage of Treg, and persistent monocytic HLA-DR down-regulation are associated with poor outcome in septic patients [4, 5, 18] , we evaluated these parameters in the last 47 septic patients enrolled in the study and explored their correlation with IDO activity. We first validated in these 47 patients that, similarly to the whole cohort, IDO activity was significantly increased and associated with disease severity at both day 0 and day 7 (data not shown Figure 2A ) n p 10 P p .008 and was significantly higher at day 7 in survivors than in nonsurvivors ( ) ( Figure 2B ). Circulating monocytes of sep-P p .02 tic patients exhibited a severe and prolonged loss of HLA-DR expression compared with control participants ( , P ! .001 P p , and at day 0, day 7, and day 14, respectively) .001 P p .03 ( Figure 2C) , with a trend toward better restoration of HLA-DR expression at day 7 in survivors compared with nonsurvivors ( ) ( Figure 2B ). Finally, the proportion but not P p .05 the absolute number of CD4 + T cells with a regulatory phenotype was elevated in septic patients at day 0 ( ) and P p .001 day 7 ( ) ( Figure 2D ) but was not predictive of death. P p .01 We found no correlation between IDO activity and either lymphocyte count, number or proportion of Treg, or monocytic expression of HLA-DR, at both day 0 and day 7.
Stimulation of IDO activity in PBMCs from healthy donors. To validate the role of circulating monocytes as IDO-producing cells, we stimulated whole PBMCs, CD14 + , and CD14 Ϫ cells from control participants by IFN-g or by agonists for TLR4 (LPS), TLR3 (poly(I:C)), and TLR9 (CpG-C). Each compound induced a strong IDO activity in PBMCs. IFN-g, LPS, and poly(I:C) directly stimulated IDO activity in purified monocytes but not in CD14 Ϫ cells ( Figure 3A ). To confirm these functional results, we then directly evaluated IDO expression. Although IDO was not constitutively expressed in human mesenchymal stem cells and was transcriptionally induced by IFN-g as described elsewhere [32] , a high level of IDO messenger RNA was detected in nonstimulated circulating monocytes, despite a low protein expression. IDO protein expression was strongly enhanced after IFN-g treatment ( Figure 3B-3C ). In agreement with the lack of TLR9 expression on human monocytes, kynurenine release remained undetectable following stimulation of purified CD14 + cells by CpG. In addition, CpG did not promote IDO activity in purified CD14
Ϫ cells, indicating that cell interactions between TLR9 + CD14 Ϫ cells, most likely pDCs, and TLR9 Ϫ CD14 + monocytes, were required to promote CpG-dependent IDO production. To further explore the mechanism of this crosstalk, we evaluated the role of IFN-a. Addition of anti-IFN-a combined with anti-IFN-ab receptor strongly reduced IDO activity in PBMCs stimulated with CpG, and IFNa promoted IDO activity by itself in normal PBMCs ( Figure  4A-4B) . Moreover, whereas CpG stimulation of whole PBMCs induced neither IFN-a nor IFN-g production by CD14
+ monocytes (data not shown), TLR9 ligation induced the synthesis of IFN-a by pDCs, as evaluated by intracellular staining ( Figure  4C ). Collectively, these data suggest that CpG-dependent IDO expression in PBMCs requires TLR9
Ϫ monocytes and IFN-a release by TLR9 + pDCs. Given previously reported alteration of NF-kB expression and activation in PBMCs from patients with sepsis [12, 33] , and the central role of NF-kB canonical pathway in TLR signaling [34] , we investigated whether IDO induction in PBMCs involved NFkB. Wedelolactone, a specific NF-kB inhibitor, strongly decreased IDO expression and activity in CD14 + cells stimulated by LPS, whereas IFN-g-dependent IDO induction was not affected (Figure 4D) . The same results were obtained using NBD peptide, a selective inhibitor of the canonical NF-kB pathway (data not shown). These findings demonstrate that NF-kB is required for LPS-mediated IDO induction in monocytes.
Stimulation of IDO activity in PBMCs from patients with sepsis. Besides their global dysfunction as antigen-presenting cells, circulating monocytes display a complex activated or deactivated status in septic patients. It was recently suggested that persistent immunosuppression after hematopoietic stem cell transplantation involves dysfunctional circulating monocytes displaying kynurenine hyperproduction spontaneously and after in vitro restimulation [35] . We tested the hypothesis that monocytes obtained from septic patients would also exhibit enhanced IDO activity. However, kynurenine concentrations were similar in unstimulated PBMCs obtained from septic patients ( mmol/L, ) and in control participants 1.49 ‫ע‬ 2.01 ; n p 10 P p .005 and , respectively). The lack of IDO activity was also P ! .001 observed when PBMCs were primed with GM-CSF, an antiapoptotic growth factor that restores in vitro monocyte function and cytokine secretion [13] . The mean level of kynurenine synthesis triggered by IFN-g was similar in PBMCs obtained from septic patients and from control participants, whereas ) and septic n p 15 patients (Sp;
) were left untreated (Co) or were stimulated during n p 12 3 days by interferon g (IFN-g) or lipopolysaccharide (LPS), before quantification of kynurenine level in cell-culture supernatants. For 8 healthy donors and 7 septic patients, PBMCs were also evaluated for their response to poly(I:C) and CpG-C (* ; ** ; *** ; ns: not P ! .05 P ! .01 P ! .001 significant).
kynurenine release following LPS ( ) and poly(I:C) P ! .001 ( ) stimulation was significantly reduced ( Figure 5 ). P p .001 Thus, circulating monocytes from septic patients were remarkable for their inability to activate IDO through TLR3 and TLR4 engagement, while they remained responsive to IFN-g stimulation. Moreover, CpG efficiently promoted IDO activity in only 2 of 7 patients ( ), compared with that in control P p .02 participants.
DISCUSSION
In this study, we demonstrated that IDO activity was (1) markedly increased during sepsis; (2) correlated with sepsis stage, with SAPS II and LOD severity scores, and was predictive of outcome; and (3) remained significantly higher than activity in control participants for at least 14 days after diagnosis, in agreement with current views that sepsis-associated immunosuppression is long-lasting. Two recent studies described IDO activity in plasma as a prognostic factor in bacteremic patients and as a risk factor for post-traumatic sepsis [36, 37] . Conversely, in studies using high-throughput microarray approaches, INDO-the gene encoding IDO-was not significantly up-regulated in septic patients [38, 39] , in agreement with our findings that an IDO increase in circulating monocytes occurs through posttranscriptional mechanisms.
We found no correlation between increased IDO activity in plasma and HLA-DR down-regulation on circulating monocytes. Thus, these alterations, even if they participate in immune deactivation and occur in the same cell type, may be driven by different processes. In agreement with the hypothesis of 2 independent mechanisms, dexamethasone induces HLA-DR down-regulation on monocytes in vitro [11, 15] but has no effect on IDO (data not shown). Likewise, we found no correlation between Treg and IDO levels in plasma, although Treg are able to directly drive antigen-presenting cells to express functional IDO [20, 40] . Interestingly, neutrophil and monocyte oxidative metabolism is increased in septic patients, both constitutively and under various stimuli [41] . Because IDO activity is modulated by intracellular redox status in human macrophages [42] , it would be interesting to evaluate further the relationships between IDO and oxidative burst in sepsis.
Using in vitro studies, we demonstrated that CD14 + monocytes are the main IDO producers within PBMCs, in response to IFN-g, LPS, and poly(I:C). We identified, as already described for dendritic cells [43] , a discrepancy between IDO expression and activity in human monocytes. Unlike poly(I:C), LPS alone is unable to induce active IDO expression in monocyte-derived dendritic cells [24, 27] . In our study, both TLR3 and TLR4 ligands increased IDO activity in purified circulating monocytes, and NF-kB was required for LPS-mediated IDO induction. Similarly, whereas IL-10 cooperates with IFN-g for IDO induction in murine dendritic cells [44] , it strongly repressed IFN-g-driven IDO activity in human monocytes (data not shown). Collectively, these results confirm that IDO induction involves different signaling pathways depending on cell type. Moreover, sepsis-related alteration of the NF-kB pathway [12, 33] could play a crucial role in the selective unresponsiveness of monocytes to NF-kB-dependent TLR stimulation, whereas IFN-g remains fully able to trigger IDO activation in an NF-kB-independent manner. Interestingly, because LPS and poly(I:C) did not induce IDO, both MyD88 and TRIF pathways seem to be altered during sepsis. Surprisingly, we observed no spontaneous IDO activity in PBMCs isolated from patients during the early phase of sepsis. Several hypotheses could explain this intriguing result. First, IDO activity could be due to expansion, recruitment, and/or activation of immunosuppressive cells within inflamed tissues rather than in peripheral blood. In agreement, a GR-1 + CD11b + population of immature myeloid cells with suppressor functions was recently identified in spleen, lymph nodes, and bone marrow during sepsis in mice [45] . Alternatively, blood monocytes could be involved in IDO activation during sepsis in humans, because CD14 + monocyte counts were significantly increased in septic patients and remained able to produce IDO in response to IFN-g stimulation in vitro. This change in the dynamic of circulating monocytes might be related to TLR-dependent stimulation of bone marrow myelopoiesis and monopoiesis by microbial components [46, 47] and could be amplified by an impaired CX3CR1-de-pendent recruitment of monocytes toward infected tissues [11] . Given the heterogeneity of circulating monocytes [48] , further studies on monocyte subset functions are warranted in both early and late phases of sepsis.
Another intriguing finding was that CpG-dependent induction of IDO in PBMCs required both CD14 + TLR9
Ϫ monocytes and CD14 Ϫ TLR9 + IFN-a-producing pDCs, fostering 2 nonexclusive hypotheses. First, circulating pDCs could produce IDO after TLR9 triggering through unidentified monocyte-derived factors. Interestingly, recombinant IFN-a was recently shown to promote IDO protein expression in pDCs within PBMCs [49] . Conversely, even if IFN-a alone did not induce IDO expression and activity in purified monocytes (data not shown), CpG-dependent IDO activity could originate from CD14 + cells, because TLR9-activated pDCs also produce TNFa, a welldescribed IDO inducer in combination with IFN-g [32, 50] . Whatever the IDO-producing cell in normal PBMCs stimulated by CpG, the TLR9 signal was unable to drive IDO activity in PBMCs of septic patients. This could be related to the dramatic decrease in Lin Ϫ HLA-DR Ϫ CD123 + circulating pDCs during sepsis (data not shown) but could also imply sepsis-related monocyte reprogramming.
The present work suggests that IDO activation during severe sepsis and septic shock could be an additional mechanism by which circulating monocytes contribute to sepsis-induced immune dysregulation. Better understanding of immune alterations during sepsis could pave the way toward new therapeutic strategies aiming to restore septic patient's immunity. As some IDO inhibitors are already under evaluation in patients with advanced malignancies, one could envision the use of small molecules targeting IDO to relieve immune suppression in severe sepsis and septic shock.
